Evidence map›Paper›PMID 42455178›Full record

ArticleMikrochimica acta2026

In situ-formed multifunctional nanozyme hydrogel for synergistic radio-immunotherapy of osteosarcoma.

Zihao Hu, Zhe Wang, Zhirong Bao, Dajiang Wang, Fuwei Yang

Abstract read
PubMed Publisher
In one paragraph

Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zihao Hu *Inner Mongolia Medical University, Inner Mongolia Clinical Medical College, Hohhot, 010017, China.
Zhe Wang *Inner Mongolia Medical University, Inner Mongolia Clinical Medical College, Hohhot, 010017, China.
Zhirong BaoDepartment of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Dajiang WangDepartment of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. wangdajiang@znhospital.cn.
Fuwei YangDepartment of Neurosurgery, Union Hospital of Jilin University, Changchun, China. yfw@jlu.edu.cn.

Funding

the National Natural Science Foundation of China 12005158
6 · The paper itself

Abstract

Osteosarcoma faces the challenges of limited drug delivery and an immunosuppressive tumor microenvironment. M1 macrophages, a type of tumor-associated macrophage, play a pivotal role in shaping tumor immune responses. A dual enzyme-mimicking nanozyme coordinated to risedronate sodium and encapsulated in a sodium alginate gel (RZRSA) was developed to enhance the radiosensitivity of osteosarcoma. After intratumoral injection, RZRSA formed a calcium alginate hydrogel in osteosarcoma owing to the presence of Ca

Indexed as

Bone NeoplasmsHydrogelsOsteosarcomaAlginatesAnimalsCell Line, TumorHumansImmunotherapyMiceAlginatesHydrogelsImmunotherapyNanozymeOsteosarcomaRadiotherapyRisedronate sodium

Identifiers

PMID42455178

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.